Clinical Trial Update: A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310) [Phase 3]

View source ↗

Summary

This entry reports the completion of a Phase 3 study evaluating RO4917838 in participants with persistent, predominantly negative symptoms of schizophrenia (NN2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• RO4917838

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED